Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials

• Main Authors: Atsushi Tanaka, Koichi Node
• Format: Article
• Language: English
• Published: BMC 2019-02-01
• Series: Cardiovascular Diabetology
• Subjects: Type 2 diabetes; Cardiovascular outcome trial; Glucose-lowering agent; Dipeptidyl peptidase-4 inhibitor; Tailored medication
• Online Access: http://link.springer.com/article/10.1186/s12933-019-0834-0

Abstract In Japan, the choice of anti-diabetic medication is officially recommended according to the patient’s glycemic condition and disease phenotype, unlike most other regions where metformin is recommended as the first-line medication. There has been an increase in the number of available glucose-lowering agents, making it necessary to select these agents based on ever-improving evidence obtained from clinical trials. For the dipeptidyl peptidase-4 inhibitor class of drugs, nine drugs are currently available on the market in Japan. Although previous cardiovascular outcome trials (CVOTs) demonstrated non-inferiority for both major adverse cardiovascular events (MACEs) and safety for some drugs of the class, the design and results of the CARMELINA trial seemed to be slightly different from earlier trials in that it showed the drugs were safe and partially effective even in patients with renal impairment. Thus, recent CVOTs on newer glucose-lowering agents have mainly focused on the major impacts of individual classes and drugs on clinical outcomes behind their glucose-lowering action. The diverse features of the classes and individual drugs may have also highlighted not only the class-effects, but also the drug-effects of glucose-lowering agents. This will lead to clinical-based evidence and assist with optimum selection of the class and/or drug for tailored medication in patients with type 2 diabetes.